1. The role of deubiquitinating enzymes in cancer drug resistance

   • Parthasaradhireddy Tanguturi
   • Kye-Seong Kim
   • Suresh Ramakrishna

   Review Article 07 March 2020 Pages: 627 - 639

   

2. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma

   • Michele Reni
   • Umberto Peretti
   • Luca Gianni

   Original Article 10 March 2020 Pages: 641 - 650

   

3. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer

   • Jiyoung Keum
   • Hee Seung Lee
   • Seungmin Bang

   Original Article 17 March 2020 Pages: 651 - 659

   

4. Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination

   • Xiaojun Liu
   • Yingjun Jiang
   • William Plunkett

   Original Article 18 February 2020 Pages: 661 - 672

   

5. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

   • Anthony W. Tolcher
   • Razelle Kurzrock
   • Li Yan

   Original Article 15 February 2020 Pages: 673 - 683

   

6. Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer

   • Soo Jin Kim
   • Kyung Hwan Jegal
   • Keon Wook Kang

   Original Article 11 March 2020 Pages: 685 - 697

   

7. A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor-κB activation

   • Ke Li
   • Yun Zhou
   • Jimin Liang

   Original Article 17 March 2020 Pages: 699 - 709

   

8. Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic–pharmacodynamic model in gastrointestinal cancer patients

   • Usman Arshad
   • Su-arpa Ploylearmsaeng
   • Max Taubert

   Original Article Open access 09 March 2020 Pages: 711 - 722

   

9. Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma

   • Qiuying Chen
   • Bin Zhang
   • Shuixing Zhang

   Original Article 02 March 2020 Pages: 723 - 730

   

10. Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: in vitro and in vivo evaluation

    • Min Li
    • Jianying Pei
    • Shuzhang Du

    Original Article 07 March 2020 Pages: 731 - 739

    

11. Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up

    • Bhavana Pothuri
    • Allison L. Brodsky
    • Franco Muggia

    Original Article 13 February 2020 Pages: 741 - 751

    

12. The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients

    • Guillemette E. Benoist
    • Inge M. van Oort
    • Nielka P. van Erp

    Original Article Open access 19 February 2020 Pages: 753 - 760

    

13. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer

    • Ou Yamaguchi
    • Hisao Imai
    • Kyoichi Kaira

    Original Article 19 March 2020 Pages: 761 - 771

    

14. Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia

    • Hiroaki Goto
    • Yuki Yoshino
    • Shoko Goto

    Original Article 06 March 2020 Pages: 773 - 783

    

15. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome

    • Xin Liao
    • Liu Huang
    • Xianglin Yuan

    Original Article 19 March 2020 Pages: 785 - 792

    

16. The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats

    • Bronwen J. Mayo
    • Kate R. Secombe
    • Joanne M. Bowen

    Original Article 14 February 2020 Pages: 793 - 803

    

17. Metabolism and pharmacokinetics characterization of metarrestin in multiple species

    • Elias C. Padilha
    • Pranav Shah
    • Xin Xu

    Original Article 17 March 2020 Pages: 805 - 816

    

18. Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation

    • Aurélie Lombard
    • Hitesh Mistry
    • Kayode Ogungbenro

    Original Article Open access 13 March 2020 Pages: 817 - 825

    

19. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma

    • Louis T. Rodgers
    • Cynthia M. Lester McCully
    • Katherine E. Warren

    Short Communication 01 January 2020 Pages: 827 - 830